0001415889-22-008896.txt : 20220819 0001415889-22-008896.hdr.sgml : 20220819 20220819160650 ACCESSION NUMBER: 0001415889-22-008896 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220817 FILED AS OF DATE: 20220819 DATE AS OF CHANGE: 20220819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavanaugh Sarah CENTRAL INDEX KEY: 0001709113 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 221180841 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-08192022_010836.xml X0306 4 2022-08-17 0000744218 Celldex Therapeutics, Inc. CLDX 0001709113 Cavanaugh Sarah C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false SVP OF CORP AFFAIRS & ADMIN. Common Stock 2022-08-17 4 M 0 31312 2.78 A 32596 D Common Stock 2022-08-17 4 S 0 31312 36.7342 D 1284 D Common Stock 2022-08-18 4 M 0 1355 9.0165 A 2639 D Common Stock 2022-08-18 4 S 0 1355 36.3757 D 1284 D Incentive Stock Option 2.78 2022-08-17 4 M 0 31312 0 D 2029-06-19 Common Stock 31312 10750 D Incentive Stock Option 9.0165 2022-08-18 4 M 0 1355 0 D 2028-06-13 Common Stock 1355 10103 D Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. As of June 13, 2022, the option is fully vested. /s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh 2022-08-19